BioTime, Inc. announced that it has received approval from The Spanish Agency of Medicines and Medical Devices (AEMPS) to begin human clinical trials of Renevia, a biomaterial used as a delivery matrix for autologous adipose derived cells to treat the loss of subcutaneous adipose tissue (lipoatrophies) arising from trauma, surgical resection, and congenital defects and disease.
According to a release, this AEMPS approval follows the earlier approval this year from the Balearic Island Ethics Committee Approval for the first of a multiphase clinical investigation of Renevia.
BioTime noted that the clinical studies will be conducted at The Stem Center in Palma de Mallorca, Spain, a patient therapy center, laboratory, and professional research facility located within the Clinica USP Palma Planas hospital in Palma. The Medical Director of The Stem Center and Principal Investigator for the Renevia studies, Ramon Lull, MD, PhD, is an expert on advanced regenerative therapies based on adipose technology. The Stem Center is owned and operated by the GID Group, Inc., Louisville, CO, USA.
Additionally, BioTime expects that the first clinical investigation, a study in 10 volunteers to demonstrate the safety of Renevia in humans, will be completed before the end of the year. Subsequent clinical studies are being planned to document the efficacy of Renevia as a delivery matrix for autologous adipose cells to restore normal skin contours in patients where the subcutaneous adipose tissue had been lost to lipoatrophy. Commenting on the approval, Dr. Lull, said, "The desire for a new and effective delivery matrix allowing for easier placement and potentially superior grafting of autologous cells is high. We are looking forward to getting started testing this novel biomaterial." Renevia is manufactured in the US in compliance with cGMP requirements and has been tested pursuant to ISO 10993 standards for Class III implantable medical devices. In these studies Renevia has been shown to be biocompatible.
Commenting on the AEMPS approval to begin clinical investigations, William, P. Tew, PhD, BioTime's Chief Commercial Officer, said "We are delighted to begin this next phase in our program for obtaining a CE Mark for Renevia. We have developed Renevia to provide plastic and reconstructive surgeons a safe and effective delivery matrix for tissue engineering and regenerative medicine applications utilizing autologous adipose cells."
Renevia is a member of BioTime's HyStem family of hydrogels. These biomaterials are designed as matrices and scaffolds for cell delivery in a variety of medicine applications. HyStem hydrogels are distributed and sold by BioTime and its distributors for pre- clinical research. BioTime's HyStem technology is covered by two issued US patents with applications pending in the EU, Canada, Japan, and Australia.
BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury.
((Comments on this story may be sent to firstname.lastname@example.org))